882855-96-1

Basic information

• Product Name: (4-AMINO-3-BROMO-PHENYL)-ACETONITRILE
• Synonyms: (4-AMINO-3-BROMO-PHENYL)-ACETONITRILE;2-(4-AMino-3-broMophenyl)acetonitrile
• CAS NO: 882855-96-1
• Molecular Formula: C₈H₇BrN₂
• Molecular Weight: 211.06
• Product Categories: Aromatic Building Blocks
• Mol File: 882855-96-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (4-AMINO-3-BROMO-PHENYL)-ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-AMINO-3-BROMO-PHENYL)-ACETONITRILE(882855-96-1)
• EPA Substance Registry System: (4-AMINO-3-BROMO-PHENYL)-ACETONITRILE(882855-96-1)

Safety Data

• Hazardous Substances Data: 882855-96-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(4-AMINO-3-BROMO-PHENYL)-ACETONITRILE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, (4-AMINO-3-BROMO-PHENYL)-ACETONITRILE serves as an intermediate in the production of agrochemicals, helping to create compounds that can be used in agriculture for pest control and crop protection.
Used in Medicinal Chemistry:
(4-AMINO-3-BROMO-PHENYL)-ACETONITRILE is utilized as a building block in medicinal chemistry for its potential to be incorporated into the structures of new compounds that can be explored for their medicinal properties and drug discovery.
Used in Organic Synthesis Research:
(4-AMINO-3-BROMO-PHENYL)-ACETONITRILE is also used as a versatile building block in the field of organic synthesis research, where it can be employed to create a variety of new organic compounds for various industrial and scientific purposes.

Upstream product

• 555-21-5 4-Nitrophenylacetonitrile 
• 3544-25-0 p-aminophenylacetonitrile 

Downstream Products

• 1449514-98-0 [3-ethyl-4-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)phenyl]acetonitrile 
• 1449515-01-8 2-[3-ethyl-4-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)phenyl]propionitrile 
• 915006-64-3 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(1H-tetrazol-5-ylmethyl)-phenyl]-amide 
• 915006-59-6 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [2-(4,4-dimethyl-cyclohex-1-enyl)-4-(1H-tetrazol-5-ylmethyl)-phenyl]-amide 
• 915006-62-1 (4-amino-3-cyclohex-1-enyl-phenyl)-acetonitrile 
• 915006-57-4 [4-amino-3-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-acetonitrile 

Relevant articles and documents

TETRACYCLIC BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Υ2, Υ3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors

Structure-activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats.

C-FMS KINASE INHIBITORS

The invention is directed to compounds of Formula II: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.